Company intelligence / Profile preview
Osivax
Lyon, Auvergne-Rhône-Alpes, Franceosivax.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Osivax has demonstrated promising results in clinical trials for its universal influenza vaccine candidate OVX836. Over Phase 1 and Phase 2a trials involving more than 1,200 subjects, the company reported a good safety profile, strong NP-specific cellular immune responses, and initial efficacy signals. A large international Phase 2b field efficacy study with over 2,800 participants is ongoing[1][3].
- Therapeutic areas
- Infectious Diseases
- Modalities
- Self-assembling nanoparticle vaccines (oligoDOM™ platform)T-cell vaccines combined with antibody-based approaches
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Meiji Seika Pharma Co., Ltd. (strategic investor and partner for infectious disease expertise)[3]
Beyond the preview
Go deeper on Osivax.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Osivax.